Xiaosong Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaosong Shi has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Byron J. Gajewski
Department of Biostatistics & Data Science, University of Kansas Medical Center
2 shared publications - Jo Wick
University of Kansas Medical Center, Kansas City, KS, United States
2 shared publications Afshin Sam
Division of Pulmonary and Critical Care, Department of Medicine, University of Arizona, Tuscon, AZ
1 shared publication- Ajay Sheshadri
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication Alex Fout
Colorado State University, Department of Statistics, 1801 Campus Delivery, Fort Collins, CO 80523-1801, United States
1 shared publicationAlexandra R. Brown
Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA
1 shared publication
Latest Publications
- Open Access
- 14 July 2024
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 144
DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization
- 14 July 2024
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 144
Open AccessDHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization
- 17 June 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (19) , 3649-3663
Improved mortality analysis in early‐phase dose‐ranging clinical trials for emergency medical diseases using Bayesian time‐to‐event models with active comparators
Emergency medical diseases (EMDs) are the leading cause of death worldwide. A time‐to‐death analysis is needed to accurately identify the risks and describe the pattern of an EMD because the mortality rate can peak early and then decline. Dose‐ranging Phase II clinical trials are essential for developing new therapies for EMDs. However, most dose‐finding trials do not analyze mortality as a time‐to‐event endpoint. We propose three Bayesian dose‐response time‐to‐event models for a secondary mortality analysis of a clinical trial: a two‐group (active treatment vs control) model, a three‐parameter sigmoid EMAX model, and a hierarchical EMAX model. The study also incorporates one specific active treatment as an active comparator in constructing three new models. We evaluated the performance of these six models and a very popular independent model using simulated data motivated by a randomized Phase II clinical trial focused on identifying the most effective hyperbaric oxygen dose to achieve favorable functional outcomes in patients with severe traumatic brain injury. The results show that the three‐group, EMAX, and EMAX model with an active comparator produce the smallest averaged mean squared errors and smallest mean absolute biases. We provide a new approach for time‐to‐event analysis in early‐phase dose‐ranging clinical trials for EMDs. The EMAX model with an active comparator can provide valuable insights into the mortality analysis of new EMDs or other conditions that have changing risks over time. The restricted mean survival time, a function of the model's hazards, is recommended for displaying treatment effects for EMD research.
- 17 June 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (19) , 3649-3663
Improved mortality analysis in early‐phase dose‐ranging clinical trials for emergency medical diseases using Bayesian time‐to‐event models with active comparators
Emergency medical diseases (EMDs) are the leading cause of death worldwide. A time‐to‐death analysis is needed to accurately identify the risks and describe the pattern of an EMD because the mortality rate can peak early and then decline. Dose‐ranging Phase II clinical trials are essential for developing new therapies for EMDs. However, most dose‐finding trials do not analyze mortality as a time‐to‐event endpoint. We propose three Bayesian dose‐response time‐to‐event models for a secondary mortality analysis of a clinical trial: a two‐group (active treatment vs control) model, a three‐parameter sigmoid EMAX model, and a hierarchical EMAX model. The study also incorporates one specific active treatment as an active comparator in constructing three new models. We evaluated the performance of these six models and a very popular independent model using simulated data motivated by a randomized Phase II clinical trial focused on identifying the most effective hyperbaric oxygen dose to achieve favorable functional outcomes in patients with severe traumatic brain injury. The results show that the three‐group, EMAX, and EMAX model with an active comparator produce the smallest averaged mean squared errors and smallest mean absolute biases. We provide a new approach for time‐to‐event analysis in early‐phase dose‐ranging clinical trials for EMDs. The EMAX model with an active comparator can provide valuable insights into the mortality analysis of new EMDs or other conditions that have changing risks over time. The restricted mean survival time, a function of the model's hazards, is recommended for displaying treatment effects for EMD research.
- Open Access
- 19 February 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 38, 101281
Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center
- 19 February 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 38, 101281
Open AccessUsing Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center
- 1 September 2021
- Published by Elsevier in Children and Youth Services Review
- Vol. 128, 106161
The mediating role of willingness to seek help on the relationship between peer victimization and mental health outcomes
- 1 September 2021
- Published by Elsevier in Children and Youth Services Review
- Vol. 128, 106161
The mediating role of willingness to seek help on the relationship between peer victimization and mental health outcomes